6 best EDC platforms for Phase IV and post-marketing studies in 2026

Your pivotal trial database took months to build and ran for two years. The post-marketing commitment attached to that same approval will run for five, across several times as many sites, most of which have never entered clinical data before, and finance has already asked why the electronic data capture (EDC) license costs nearly what it did for the registration study. Viedoc's EDC software is built for that shape of work, with a no-code Designer your own data managers run, unlimited user seats however many sites you open, and a native Japan post-marketing surveillance (PMS) module, proven across 8,000-plus studies in 75-plus countries. This comparison reviews six EDC platforms for Phase IV and post-marketing studies across amendment velocity, regional regulatory coverage, licensing economics at high site counts, and site burden.

Post-marketing work carries the regulatory weight of a registration trial and almost none of its budget. You might be running a use-results survey under Japan's Good Post-marketing Study Practice (GPSP) ordinance, post-market clinical follow-up (PMCF) under the EU Medical Device Regulation (MDR), or a five-year safety registry attached to a US label commitment, each asking a different data collection shape of the same small team. The people entering data are community physicians and their staff, not trained coordinators, so every extra click becomes a query.

Enterprise platforms are priced and configured for the pivotal trial, which means long build cycles and vendor-side programming for changes you'll need annually across five years. Generic survey tools fail the first time an inspector asks for a field-level audit trail. The platforms below are judged on whether they can carry a low-intensity, long-duration, high-site-count study without the cost structure breaking it.

Best EDC platforms for post-marketing studies: quick comparison

The 6 best EDC platforms for post-marketing studies reviewed

These six eClinical platforms are the options sponsors and contract research organizations (CROs) most often evaluate for post-marketing work.

1. Viedoc

Viedoc's EDC software puts study build and amendment in your own team's hands through a no-code, drag-and-drop Designer, which counts for more here than anywhere else, because a five-year surveillance study will be amended repeatedly before it locks. Minor changes typically take 1–3 working days, made by the certified designer who built the study. The platform carries a 100% FDA inspection pass rate across 8,000-plus studies and 30,000-plus sites.

Unlimited user seats mean opening 300 low-activity community sites costs no more in licensing than opening 30, and Viedoc's ePRO software carries the recurring patient follow-up registries depend on. Medical device company Sonex Health ran three post-market studies this way, reaching at least 98% visit compliance across 1,300-plus participants at 33 sites, with 85% completing visits after one reminder.

Viedoc is ISO 27001, ISO 9001, and SOC 2 certified and supports 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, HIPAA, GAMP 5, and CDISC, hosted on Microsoft Azure with 99.99% uptime. For Japan, it is PMDA ERES and APPI compliant, and Viedoc PMS handles booklet data collection, the Kaifu process, progress management, and query management in one application.

"The advantages of using Viedoc are that the platform is very user-friendly, you don't need to have any prior knowledge of Viedoc as there are comprehensive training resources available that are very well designed and easy to follow." – Ana-Marija I.

Verified proof points:

• Study scale: 8,000+ studies across 75+ countries and 30,000+ sites
• Licensing: Unlimited user seats, no per-user fees, study-based licensing
• Japan PMS: Native module with booklet data collection and Kaifu support; PMDA ERES and APPI compliant
• Amendments: Minor mid-study changes typically in 1–3 working days
• Compliance: 21 CFR Part 11, ICH GCP, GDPR, Annex 11, HIPAA; ISO 27001, ISO 9001, and SOC 2 certified
• Support: 24/7 across global offices, in 40+ languages

2. Medidata

Medidata offers Rave EDC, the electronic data capture application at the center of the Medidata Platform, which aggregates and reconciles data across connected modules. Rave captures site, patient, and lab data from Phase I through Phase IV and applies protocol amendments and mid-study changes without system downtime. For smaller and later-phase work, Medidata offers Rave Lite, a version the company positions for Phase I, Phase IV, and medical device post-market studies, with a flexible pricing model and faster study builds. Post-trial and registry follow-up is handled by a separate application, myMedidata Registries. Rave connects to eConsent, eCOA, RTSM, imaging, and safety reporting, and Rave Companion lets sites populate EDC forms from electronic health record (EHR) data. Medidata is a Dassault Systèmes company.

3. Veeva

Veeva provides Vault EDC as a module of Vault Clinical Data Management (Vault CDMS), a single cloud application covering EDC, coding, data cleaning, and reporting. Studies are configured using drag-and-drop tools rather than coded, and mid-study design amendments are applied without migrations or downtime. Vault CDMS sits within the wider Vault Clinical Suite alongside CTMS, eTMF, study start-up, payments, and study training, and Veeva Connections move data between those applications, including subject and randomization data from RTSM and protocol deviation records into CTMS. Veeva reports that Vault EDC has enabled study build in as little as seven weeks. The architecture is aimed at organizations that want clinical operations and data management unified on one platform rather than buying a standalone module.

4. Castor

Castor offers a cloud EDC and clinical data management platform with distinct study-type configurations for interventional trials, chart review, patient registries, and post-market clinical follow-up. Its PMCF offering covers eCRF design for registry, survey, and chart review studies, ePRO for recurring follow-up at intervals such as one, three, and five years, EHR integration through an application programming interface (API), and structured exports for Periodic Safety Update Report and Clinical Evaluation Report workflows. Castor Catalyst applies AI-assisted extraction to source documents and EHR data, with every output confidence-scored for human review before it enters the study record. The platform is validated against 21 CFR Part 11, GDPR, and ISO 27001, and Castor states its PMCF support is aligned to EU MDR 2017/745 and ISO 14155.

5. Medrio

Medrio provides a clinical data management system and EDC that sponsors and CROs configure, adapt, and manage without a programmer, using no-code tools. The platform is positioned for research from early phase through post-market, with ePRO/eCOA, eConsent, RTSM, CTMS, and eTMF integrated on one platform. Medrio also sells clinical data services and project management support spanning database build, data management, biostatistical analysis, and regulatory-ready outputs, which suits teams running post-market programs without adding headcount. Import and export APIs connect the platform to wearables and sensors, lab systems, analytics tools, and data warehouses. Medrio has worked in clinical research for more than 20 years, supports sites across more than 30 countries, and maintains a MedTech industry offering and a CRO partner program.

6. Datatrak

Datatrak offers a dedicated post-market surveillance application alongside its EDC, covering Phase IV requirements and both drug safety and device post-market surveillance in one cloud platform. The PMS application shares the reporting and configuration model of the company's EDC, with real-time access, filtering, and export of study data on demand. Mid-study changes are applied without study downtime or data migration, which matters across the multi-year follow-up periods these studies run to. The wider platform covers CTMS, eTMF, RTSM/IWRS, eConsent, ePRO/eCOA/eSource, local lab import, and EMR/EHR connectivity, with trial design and data management services alongside it. Datatrak's stated customer categories include CROs, sponsors, medical device companies, and registry and real-world evidence (RWE) studies.

What to look for in EDC platforms for Phase IV and post-marketing studies

Amendment velocity across a multi-year follow-up window

A pivotal trial database is built once and amended a handful of times. A five-year surveillance study absorbs protocol revisions, new safety endpoints, regulator questions, and changes to the site network, each landing on a database already holding live patient data. What matters is not the vendor's initial build estimate but how quickly a change reaches production without pausing collection.

Best-in-class means minor changes in days rather than weeks, no vendor handoff for routine edits, and version control that keeps every prior form definition intact for audit. Viedoc applies minor mid-study changes in 1–3 working days, without downtime. Ask for amendment turnaround in writing, separately from the build timeline.

Regional post-market coverage rather than general GCP compliance

Post-market obligations are set locally. Japan requires use-results surveys under the GPSP ordinance, with booklet data collection and the Kaifu review process that pharma-first global platforms rarely handle natively. EU device follow-up runs to MDR Annex XIV Part B and ISO 14155, US commitments sit under 21 CFR Part 822, and satisfying one won't automatically satisfy the others.

Check whether PMDA ERES and APPI compliance ship as standard, whether booklet and Kaifu handling exist in the product itself, and whether device exports map to Periodic Safety Update Report formats. Viedoc's post market surveillance software is selected as a study type at setup, with no separate license. If a vendor answers a Japan PMS question with custom development, price it as a project rather than a feature.

Licensing economics at high site counts and low data volume

Post-marketing studies invert the economics of a trial. Data per patient is thin, but site and user counts are high, follow-up runs for years, and every community physician, coordinator, monitor, and safety reviewer needs an account. Per-seat licensing that looked reasonable across 25 investigator sites becomes the largest line in the budget across 300.

Model the license across the full surveillance period at your real site count, including read-only regulatory and quality assurance users. Unlimited seats and study-based licensing remove the incentive to ration access, which is what teams do when seats carry a cost, and rationed access is how data entry backs up.

Site burden at sites that don't run research routinely

The sites in a post-market study are usually the ones using your product in ordinary care. They have no dedicated coordinator, no research budget, and little appetite for a two-day training course, and their engagement decides whether the dataset is usable.

Best-in-class means a site user can complete a visit form without formal instruction, and that patient follow-up runs on automated reminders rather than site chasing. Multi-language capture matters too, since post-market populations sit wherever the product is sold. Underestimate this and the monitoring budget goes on sites that entered almost nothing.

How to choose the right EDC platform for Phase IV and post-marketing studies

Step 1: Define which regulator sets your requirements

Start with the obligation rather than the feature list. A Japan re-examination commitment, an EU MDR PMCF plan, and an FDA post-approval study impose different data structures, review workflows, and reporting outputs. Whichever drives your program should shape the shortlist first.

Step 2: Assess whether one platform can carry trials and commitments

Decide whether post-market work belongs on the same platform as your interventional studies. One validated environment lets you reuse form libraries and avoids a second validation and training burden, while splitting them buys specialist depth at the cost of two vendors. Where the post-market portfolio is set to grow, reuse usually wins.

Step 3: Scrutinize the cost of the study's fifth year, not its first

Price the whole surveillance period. Ask how license fees behave when you double the site count in year two, what you pay during long low-activity stretches, and whether data access after lock is included or billed. The cheapest year-one quote is frequently the most expensive five-year commitment.

Step 4: Test the platform with a site user, not a data manager

Put a live form in front of someone who resembles your actual sites. A physician's assistant completing a follow-up visit unaided tells you more about your future data quality than any walkthrough of the designer environment. Request a sandbox and run that test before you shortlist.

Step 5: Choose the platform that fits your operating model

Weigh how the platform suits the way your team works over years rather than months, from who can amend it to whether licensing survives a growing site network. Viedoc's EDC platform is built around that profile, with in-house no-code configuration, unlimited user seats, and a native Japan PMS module. If that matches your program, you can book a demo or request a proposal to see it against your own study design.

Frequently asked questions

What is the best EDC platform for Phase IV and post-marketing studies?

Viedoc's EDC software is the strongest fit for Phase IV and post-marketing studies, combining unlimited user seats for high site counts, in-house no-code amendments turned around in 1–3 working days, and a native Japan PMS module covering booklet data collection and the Kaifu process. Its compliance position spans 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, HIPAA, and PMDA ERES, with a 100% FDA inspection pass rate across 8,000-plus studies. Castor is a credible alternative for EU MDR post-market clinical follow-up, with dedicated registry and chart review study types. Datatrak offers a dedicated post-market surveillance application, and Medidata provides a Rave Lite tier positioned for Phase IV and device post-market work, though the full platform is weighted toward large registration programs.

What should you look for in an EDC platform for post-marketing studies?

Prioritize the factors that compound over a long follow-up period. Amendment turnaround matters more than initial build speed, because a multi-year study absorbs changes annually while holding live data. Licensing model matters more than headline price, since these studies open many low-activity sites and per-seat fees scale badly against that shape. Confirm your regional obligation is a supported study type rather than a custom configuration, and test usability with someone who resembles your real site staff.

How long does it take to build and deploy a post-marketing study on a modern EDC platform?

It depends on complexity and whether you build in-house or use vendor services, but modern no-code platforms have shortened this from months to weeks. Self-service teams configuring straightforward observational or registry designs can have a database live in days. Studies built through professional services typically take around 8 to 12 weeks from work order to go-live, with expedited delivery on simpler designs often completed in about a month. For a surveillance study, the more useful question is amendment turnaround, since the database will change several times before it locks.

Which EDC platforms support Japan post-marketing surveillance studies?

Viedoc offers a native Japan PMS module built for the requirements set by the GPSP ordinance, including booklet data collection, the Kaifu process, PMS-specific dashboards, progress management, and query management, inside the same application as its core EDC. It is PMDA ERES and APPI compliant, is selected as a study type when the study is created in Viedoc Admin, and needs no extra designer training for certified teams. Platforms designed around pharmaceutical registration trials generally require custom development or a third-party add-on to meet these requirements. If Japan is in scope, ask each vendor to demonstrate booklet and Kaifu handling in the product itself.

What compliance documentation should a quality assurance team expect for a post-marketing study?

Expect 21 CFR Part 11, ICH GCP, and GDPR compliance as a baseline, with Annex 11, HIPAA, and regional frameworks such as PMDA ERES applied where your data and populations require them, plus a complete field-level audit trail and validation to recognized standards. Because post-market studies often outlive the team that set them up, documentation of every mid-study change and prior form version matters as much as the current configuration. Viedoc is ISO 27001, ISO 9001, and SOC 2 certified and provides the Viedoc Inspection Readiness Packet to every customer as structured audit-readiness documentation. Confirm what a vendor supplies as standard before the study starts, not once an inspection date is set.

Making the right EDC choice for Phase IV and post-marketing studies

The six platforms reviewed here share a direction of travel: cloud delivery, configurable forms without code, and post-market work treated as a defined study type rather than a repurposed trial database. Where they diverge is weight, from enterprise suites offering a lighter tier for later-phase studies to platforms whose post-market application is the product itself. The global eClinical software market sits above $11 billion in 2025 and is growing at roughly 14% a year, with Phase IV, registry, and observational work among the segments pulling that growth.

Matching platform to profile turns on a few variables: how many post-market studies you'll run, the regulator setting your requirements, your site count and its likely growth, and how much you configure in-house. A sponsor with one EU MDR follow-up study weights these differently from a CRO delivering surveillance programs across regions. US buyers often prioritize speed and return on investment, while EMEA and APAC buyers weight compliance credentials and vendor stability.

Post-market studies routinely outlive the people who set them up, so the platform you can still amend, staff, and afford in year five matters more than the one that demonstrates best in week one.

Why Viedoc is the best EDC choice for Phase IV and post-marketing studies

Post-marketing studies fail on economics and site engagement long before they fail on features, and that is what Viedoc's EDC software is designed around. Unlimited user seats mean a growing site network doesn't reprice your study, and the no-code Designer keeps amendments with your own team, turning minor changes around in 1–3 working days.

The regional depth is what makes it work outside one jurisdiction. Viedoc PMS handles Japan's booklet data collection, Kaifu process, progress management, and query management natively, in the same Designer environment your team already knows and with no separate license. Across 40-plus languages and 75-plus countries, the same platform carries device follow-up, registries, and observational programs, backed by 24/7 support and certified designer training.

The credentials hold up to inspection. Viedoc is ISO 27001, ISO 9001, and SOC 2 certified, supports 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, HIPAA, and PMDA ERES, and carries a 100% FDA inspection pass rate backed by the Viedoc Inspection Readiness Packet, across 7,500-plus studies and 30,000-plus sites since 2003.

If you want a platform your own team can amend, staff, and afford across a five-year commitment, Viedoc is built for exactly that. Book a demo or request a proposal and the team will walk through amendment turnaround, regional compliance, and licensing against your own portfolio.